Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

Concerns raised over India’s approval of COVID-19 vaccine with incomplete data

4
SHARES

The All India Drug Action Network has said it is “shocked” India has given approval to Covaxin, a COVID-19 vaccine with a lack of peer reviewed safety and efficacy data.

COVID-19 vaccine

Following India’s approval of the internally developed Covaxin COVID-19 vaccine, experts have raised concerns over whether the jab should have been authorised without sufficient publication of its safety and efficacy data. The vaccine has been given permission to be used “in clinical trial mode… specifically in the context of infection by mutant strains.” 

According to BBC News, Covaxin was granted Restricted Emergency Use (REU) approval in India at the same time as the Oxford-AstraZeneca COVID-19 vaccine, AZD1222. However, the only data on humans has been published in pre-prints, meaning that no peer reviewed Phase I or Phase II results have been released. Furthermore, the Phase III trial to study the vaccine, produced by Bharat Biotech, is incomplete. 

The All India Drug Action Network (AIDAN) has said that it is “shocked” and that there are “intense concerns arising from the absence of the efficacy data” as well a lack of transparency that would “raise more questions than answers and likely will not reinforce faith in our scientific decision making bodies.” AIDAN has requested the Drugs Controller General of India (DCGI), VG Somani, to reconsider the recommendation to use Covaxin. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

However, Indian Prime Minister Narendra Modi has hailed the vaccine as a “game changer” and Somani, said that Covaxin was “safe and provides a robust immune response.”

Both the Covaxin and Oxford-AstraZeneca vaccines can be stored at normal refrigeration temperatures. 

In an interview with the Associated Press, Adar Poonawalla, whose Serum Institute of India (SII) is manufacturing the AstraZeneca Oxford vaccine, said this vaccine was given emergency authorisation on the condition that it would not be exported outside India. Poonawalla also said that his company was prohibited from selling the inoculation on the private market.

Why cold chain requirements are not holding COVID-19 vaccines back…

One response to “Concerns raised over India’s approval of COVID-19 vaccine with incomplete data”

  1. Iben says:
    20 January 2021 at 3:19 pm

    Nice information.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via